Sirolimus
Approved · EMAAlso known as Felycin, Fyarro, Hyftor, Rapamune+4 more
Felycin, Fyarro, Hyftor, Rapamune, (-)-Rapamycin, Rapamycin, Sirolimusum, Sirolimús.
Recent clinical, regulatory, research and industry developments relating to this drug.
Autism-Like Traits in Mice Improved After Single Rapamycin Dose
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.
PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?
Rapamycin extenuates experimental colitis by modulating the gut microbiota.
Autophagy and autophagy signaling in Epilepsy: possible role of autophagy activator.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
Evidence ↗Indication: Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune… Show full indicationShow less
Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued. Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Sirolimus Combined With All Trans Retinoic Acid for the Treatment of Auto-Immune Anemia
Recent completions
Trials that read out recently, adding to the completed evidence base.
Sirolimus for Nosebleeds in HHT: A Phase II Pilot Study
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine5
- GeroScience2
- Investigative ophthalmology & visual science2
- American journal of ophthalmology1
- Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists1
- Annals of the American Thoracic Society1
- Lee HS4
- McCormack FX4
- Strange C4
- Barker AF3
- Brantly ML3
- Brown KK3
- Chapman JT3
- Chew EY3
- National Eye Institute4
- University of Cincinnati3
- Cincinnati Children's Hospital Medical Center2
- College of Medicine2
- Medical University of South Carolina2
- University of California2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Sirolimus, with 6 overlapping disease areas.
Studied across 6 of the same disease areas as Sirolimus in the shared literature.
Studied across 4 of the same disease areas as Sirolimus in the shared literature.
Studied across 4 of the same disease areas as Sirolimus in the shared literature.
Studied across 4 of the same disease areas as Sirolimus in the shared literature.
Studied across 4 of the same disease areas as Sirolimus in the shared literature.
Studied across 4 of the same disease areas as Sirolimus in the shared literature.
Studied across 3 of the same disease areas as Sirolimus in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.